249 241

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

Inventor: Fahri Saatcioglu

Serial No: U.S. National Phase Application of PCT/IB00/00673

Filed:

May 19, 2000

For:

Differentially Expressed

Genes in Prostate Cancer

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

PRELIMINARY AMENDMENT

The Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Dear Sir:

Please enter the following preliminary amendment:

IN THE CLAIMS

- 5. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
- 6. (Amended) The polynucleotide of [any one of] claim 1[, 3, or 4] wherein the expression of the polynucleotide is dependent on at least one of an androgen, a progesterone, an estrogen, and a glucocorticoid.
- 33. (Added) The polynucleotide of claim 3 wherein the polynucleotide is expressed *in vivo* in a prostate cancer cell.
- 34. (Added) The polynucleotide of claim 4 wherein the polynucleotide is expressed in vivo in a prostate cancer cell.

ļ.i.